Clinical Trials Sponsored by Jiangsu HengRui Medicine Co.

Total 688 results

Wuhan Union Hospital, China
Jiangsu HengRui Medicine Co., Ltd.; CSPC ZhongQi Pharmaceutical Technology...

Not yet recruiting

Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Completed

A Phase I Study of SHR1459 in Healthy Subjects

Health, Subjective

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
The Third Xiangya Hospital of Central South University

Completed

Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects

Advanced Solid Tumor

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 in Combination With GEMOX in Patients With Advanced BTC

Cholangiocarcinoma | Biliary Tract Cancer

China
Wuhan Union Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA

Aplastic Anemia | Primary Immune Thrombocytopenia

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

HER2-positive Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Completed

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Breast Cancer

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.; Peking University Shougang Hospital

Withdrawn

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Progression | Pediatric Cancer | Effect of Drugs

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

China
Zhongshan Hospital Xiamen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

Stage IV Gastric Cancer With Metastasis
Wuhan Union Hospital, China
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients

Primary Immune Thrombocytopenia
Peking University People's Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer

Germline BRCA-mutated HER2-negative Breast Cancer

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma

Sarcoma

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Borderline Resectable Pancreatic Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Advanced Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer (APPROVE)

Platinum-resistant Recurrent Ovarian Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University; Shanghai Pulmonary Hospital, Shanghai, China

Suspended

A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Lung Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Terminated

Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Terminated

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Gastroenteropancreatic Neuroendocrine Tumor

China
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Completed

Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Completed

A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer

Metastatic Renal Cell Cancer | Renal Cell Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University; Peking University Cancer Hospital & Institute

Completed

A Study of Famitinib in Patients With Advanced Colorectal Cancer

Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Cancer Recurrent

China
Jiangsu HengRui Medicine Co., Ltd.
Beijing Friendship Hospital; Beijing 302 Hospital; Beijing Anzhen Hospital

Unknown

Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

Non-hypovolemic Non-acute Hyponatremia

China
Fujian Cancer Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.; SunWay Biotech Co., LTD.

Not yet recruiting

Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma

Liver Metastases | Malignant Melanoma
Jiangsu HengRui Medicine Co., Ltd.
307 Hospital of PLA; Peking University Cancer Hospital & Institute

Completed

A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies

Advanced Solid Malignancies

China
Jiangsu HengRui Medicine Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Completed

Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer (BLTN-Ic)

Metastatic Breast Cancer

China
The First Affiliated Hospital of Zhejiang Chinese...
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer

Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
People's Liberation Army General Hospital of Chengdu Military Region

Completed

A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

Type 2 Diabetes

China
Peking University Cancer Hospital & Institute
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Metastatic Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial

Breast Cancer | Hormone-receptor Positive Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (Artemis)

Breast Cancer

China
Wuling Ou
Jiangsu HengRui Medicine Co., Ltd.; Hubei Clinical Research Collaboration Group

Unknown

Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

Nonsmall Cell Lung Cancer

China
RenJi Hospital
Jiangsu ZuoYou Medicine Co., Ltd.

Completed

Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer

Early-stage Breast Cancer | Breast Cancer Invasive | HER2 Low Breast Carcinoma | Hormone-receptor-positive Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Breast Cancer | Neoadjuvant Therapy | Hormone Receptor-positive Breast Cancer | HER2-low-expressing Breast Cancer

China
Nanfang Hospital of Southern Medical University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients (PANORAMA)

Chemotherapy | Immunotherapy

China
The Central Hospital of Lishui City
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging

Nephrogenic Fibrosing Dermopathy

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Prostate Cancer | Biochemical Recurrence

China
Jiangsu HengRui Medicine Co., Ltd.
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Unknown

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Recurrent and Metastatic Gastric Cancer

China
Yue Han
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

Unresectable Hepatocellular Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.; Beijing gene plus technology co., LTD

Completed

Apatinib in Refractory Colorectal Cancer

Colorectal Neoplasms

China
Sixth Affiliated Hospital, Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.; Nanjing Geneseeq Technology Inc.

Recruiting

Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer

Advanced Esophageal Cancer

China
Peking University First Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.; Beijing Biote Pharmaceutical Co.,Ltd

Recruiting

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Salivary Gland Neoplasm Duct

China
Jiangsu ShengDiYa Medicine Co., Ltd.
Dongguan People's Hospital

Unknown

Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

Nonsquamous Nonsmall Cell Neoplasm of Lung
Institute of Hematology & Blood Diseases Hospital...
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Recruiting

Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

Non Severe Aplastic Anemia | Untreated

China

Clinical Trials Sponsored by Jiangsu HengRui Medicine Co.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations